Global research and development of new antibiotics is seriously inadequate


Release time:

2017-11-01

It was learned from the World Health Organization representative office in China on September 21 that on September 20, Geneva local time, WHO released a report entitled "Antimicrobial Agents in Clinical Development: Analysis of Clinical Development of Antimicrobial Agents (including Antituberculosis Drugs). The report pointed out that the current global research and development of new antibiotics is seriously insufficient, and it is difficult to cope with the growing threat of microbial drug resistance. At present, most drugs entering the clinical stage are only improvements to existing types of antibiotics and only provide short-term solutions.

The report points out that for drug-resistant tuberculosis, which causes about 250000 deaths worldwide each year, only two new antibiotics have entered the market in the past 70 years, and there are very few potential treatment options. The report also identifies 51 new antibiotics and biologics currently in clinical development, with WHO classifying only eight as innovative treatments. For gram-negative pathogens Acinetobacter and Enterobacteriaceae such as Klebsiella and Escherichia coli, there is still a lack of treatment options. In addition, there are few oral antibiotics in development, and oral drugs are the basic agents for out-of-hospital treatment of infections.

WHO Director-General Dr Tedros said: "There is an urgent need for more investment in the development of antibiotic-resistant infections, otherwise we will be forced to return to the days when minor operations were also life-threatening."